Stay updated with breaking news from Severe Asthma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Only 14.5% of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40% of academic pulmonary and allergy clinicians have not adopted this optimal therapy, according to research published at the ATS 2024 International Conference.
People living with severe asthma have been overlooked and underserved for too long. Timely, equitable and high-quality care for this condition needs to be an integral part of every health system.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International...
The maintenance treatment for severe asthma with an eosinophilic phenotype originally was approved for patients aged 12 years and older.
A multivariable analysis showed that, in a cohort of asthma patients, being at high risk for OSA, women, having uncontrolled rhinitis, and GINA steps 4-5 were linked to uncontrolled asthma.